Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 413 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
Patents for C07D 413 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms (64,687)
11/2001
11/29/2001WO2001090081A1 Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
11/29/2001WO2001030780A3 Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation
11/29/2001WO2001028996A3 Pyrrolidine derivatives, their preparation and their use as inhibitors of neuraminidases
11/29/2001WO2000039114A3 Substituted oximes and hydrazones as neurokinin antagonists
11/29/2001US20010047031 Heterocyclic compounds useful as NMDA receptor selective subtype blockers
11/29/2001US20010047019 3-Aminopyrazole inhibitors of cyclin dependent kinases
11/29/2001US20010047006 Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
11/29/2001US20010046987 Potent activity against Grampositive and Gramnegative bacteria
11/29/2001US20010046985 Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection
11/29/2001CA2410294A1 Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides
11/29/2001CA2409998A1 Benzodiazepine derivatives as app modulators
11/28/2001EP1157998A1 Heterocyclic compounds, intermediates thereof and elastase inhibitors
11/28/2001EP1157991A2 Herbicidal imidazolidinetrione and thioxo-imidazolidinediones
11/28/2001EP1157022A1 Pyridine compounds and their pharmaceutical use
11/28/2001EP1157021A1 Sulfamato hydroxamic acid metalloprotease inhibitor
11/28/2001EP1157019A1 4-alkenyl (and alkynyl) oxindoles as inhibitors of cyclin-dependent kinases, in particular cdk2
11/28/2001EP1157018A1 A process for the preparation of taxanes from 10-deacetylbaccatin iii
11/28/2001EP1157011A1 4-amino- quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases
11/28/2001EP1157010A1 Pyrazole-3-on-derivative as factor xa inhibitors
11/28/2001EP1156807A1 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
11/28/2001EP0770068B1 Conformationally rigid bicyclic and adamantane derivatives useful as alpha 2-adrenergic blocking agents
11/28/2001EP0712394B1 Arthropodicidal oxazolines and thiazolines
11/28/2001CN1324351A Method for the preparation of citalopram
11/27/2001US6323235 Benzene-condensed heterocyclic derivatives and their uses
11/27/2001US6323217 Cardiovascular disorders
11/27/2001US6323212 Method for reducing pain, which comprises administering an effective analgesic amount of the morphinan derivative
11/27/2001US6323154 3-aryluracils and intermediates for their preparation
11/27/2001CA2041835C Cyclohexenone oxime ethers, their preparation and their use as herbicides
11/22/2001WO2001087879A1 New thiochromane derivatives and their use as thrombin inhibitors
11/22/2001WO2001087866A1 Cyclohexyl derivatives and their use as therapeutic agents
11/22/2001WO2001087862A2 Biologically active 4h-benzo[1,4]oxazin-3-ones
11/22/2001WO2001087861A2 Methods of treatment using benzoxazinones as peroxisome proliferator activated receptor gamma modulators
11/22/2001WO2001087859A1 Naphthol derivatives
11/22/2001WO2001087854A1 Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
11/22/2001WO2001087845A2 N-containing heterocyclic compounds and their use as 5-ht antagonists
11/22/2001WO2001087839A1 Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity
11/22/2001WO2001087837A1 Process and intermediates for the preparation of 1-(9h-carbazol-4-yloxy)-3-[2-(2-methoxy-phenoxy)-ethylamino]-propan-2-ol, carvedilol or acid addition salts thereof
11/22/2001WO2001087834A1 Melanin-concentrating hormone antagonist
11/22/2001WO2001087830A2 Substituted thioacetamides
11/22/2001WO2001087288A2 Method of treating vaginal dryness with nicotinic acetylcholine receptor agonists
11/22/2001WO2001005769A3 Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation
11/22/2001US20010044535 Heterocyclic compounds containing a guanidine mimic, for inhibition of cell adhesion, treatment of angiogenesis disorders, inflammation, cancer metastasis, diabetic retinopathy, thrombosis, restenosis, macular degeneration
11/22/2001US20010044445 Azole inhibitors of cytokine production
11/22/2001US20010044435 Antitumor agents, treatment of the lungs and respiratory tract
11/22/2001CA2410077A1 Cyclohexyl derivatives and their use as therapeutic agents
11/22/2001CA2409445A1 Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
11/22/2001CA2409116A1 Substituted thioacetamides
11/22/2001CA2408913A1 Melanin-concentrating hormone antagonist
11/22/2001CA2407258A1 Pharmaceutically active piperidine derivatives, in particular as modulators of chemokine receptor activity
11/22/2001CA2407222A1 New thiochromane derivatives and their use as thrombin inhibitors
11/22/2001CA2407103A1 Process and intermediates for the preparation of 1-(9h-carbazol-4-yloxy)-3-[2-(2-methoxy-phenoxy)-ethylamino]-propan-2-ol, carvedilol or acid addition salts thereof
11/21/2001EP1156049A1 Substituted heterocyclic compounds, their process of preparation and pharmaceutical compositions containing them
11/21/2001EP1156048A1 Heteroaroyl-isoxazoles and their use as herbicides
11/21/2001EP1156043A2 Drugs that enhance synaptic responses mediated by ampa receptors
11/21/2001EP1155006A1 Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical composition containing them
11/21/2001EP1154997A1 Pharmaceutically active compounds and methods of use thereof
11/21/2001EP1154774A1 Quinazoline derivatives as angiogenesis inhibitors
11/21/2001EP1154773A2 Use of antagonists of pg-e for the treatment of neuropathic pain
11/21/2001EP0914319B1 Diarylalkyl cyclic diamine derivatives as chemokine receptor antagonists
11/21/2001EP0892792B1 Process to prepare oxazolidinones
11/21/2001EP0832082B1 N-heteroaryl-pyridinesulfonamide derivatives and their use as endothelin antagonists
11/21/2001EP0831910B1 Epoxy-steroidal aldosterone antagonist and angiotensin ii antagonist combination therapy for treatment of congestive heart failure
11/21/2001CN1323396A Endogenous constitutively activated G protein-coupled orphan receptors
11/21/2001CN1323295A AZA-bicycles which modulate the inhibition of cell adhesion
11/21/2001CN1075074C Sulfonyl azaleneone compound
11/21/2001CN1075073C Hetero-aromatic ring substituted phenyloxazolidinone antimicrobials
11/21/2001CN1075072C Oxazolidinone derivatives their preparation and use
11/21/2001CN1075070C Substituted A2a-and diazacycloheptane and cyclooctane compounds and their use
11/21/2001CN1075064C New benzoxazinedione derivatives, and producing process thereof and use
11/21/2001CN1075062C 乙酸衍生物 Acetic acid derivatives
11/21/2001CN1074926C Antiarrhythmic benzodiazepines
11/20/2001US6320047 Substituted aryl or heteroarylamides having retinoid-like biological activity
11/20/2001US6319938 Prophylactic or therapeutic drug for renal diseases
11/20/2001US6319937 Isoxazoline fibrinogen receptor antagonists
11/20/2001US6319935 Used in treatment of elevated intraocular pressure, non insulin-dependent diabetes, male impotence and obesity
11/20/2001US6319932 Useful for treating benign prostatic hyperplasia
11/20/2001US6319921 Aromatic heterocyclic compound as antiinflammatory agents
11/20/2001US6319920 Muscarinic receptor antagonist used in gastrointestinal, genitourinary tract, respiratory tract, cardiovascular system, central nervous system disorders and in anesthesiology and ophthalmology
11/20/2001US6319916 Heterocyclic compounds, their production and use
11/15/2001WO2001085729A1 Novel vitronectin receptor antagonists
11/15/2001WO2001085725A1 Piperazine and piperidine compounds
11/15/2001WO2001085724A1 Gastrin and cholecystokinin receptor ligands (iii)
11/15/2001WO2001085723A1 Gastrin and cholecystokinin receptor ligands (ii)
11/15/2001WO2001085722A1 Heterobicyclic sulfonamides and their use as platelet adp receptor inhibitors
11/15/2001WO2001085714A1 Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by the np y5 receptor
11/15/2001WO2001085700A2 Hiv replication inhibiting pyrimidines and triazines
11/15/2001WO2001085168A1 Use of compounds having combined dopamine d2, 5-ht1a and alpha adrenoreceptor agonistic action for treating cns disorders
11/15/2001WO2001057043A8 Method for producing sulfonyl imidazole derivatives by phase transfer catalysis
11/15/2001WO2001046163A3 3-nitro-dihydro-isoxazoles and oxazines and their use as microbicides
11/15/2001WO2001040185B1 Compounds, compositions, and methods for stimulating neuronal growth and elongation
11/15/2001WO2001014339A3 Fungicidal heterocyclic aromatic amides and their compositions, methods of use and preparation
11/15/2001US20010041728 With thiourea, thioamide, or dithiocarbamate functionality; (S)-N-(((3-(3-fluoro-4-morpholinyl)phenyl)-2-oxo-5 -oxazolidinyl)methyl)thioacetamide for example; treats multiple-resistant staphylococci
11/15/2001US20010041726 Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
11/15/2001US20010041714 Serotonin-7 (5-HT7); treatment of central nervous system disorders such as sleep disorders, depression and schizophrenia; for example 1,3-dihydro-2-((4-(4-fluorophenyl)-4-oxobutyl))isoindole
11/15/2001US20010041702 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)-phenyl)ethoxy)-3-(S)-(4 -fluoro)phenyl-4-(3-(5-oxo-1H,4H-1,2,4-triazolo)methylmorpholine; treating neuropathy, emesis, nervous system disorders; thermodynamic stability for drugs
11/15/2001CA2408293A1 Novel vitronectin receptor antagonists
11/15/2001CA2408156A1 Heterobicyclic sulfonamides and their use as platelet adp receptor inhibitors
11/15/2001CA2406634A1 Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by the np y5 receptor
11/15/2001CA2405758A1 Use of compounds having combined dopamine d2, 5-ht1a and alpha adrenoreceptor agonistic action for treating cns disorders
11/14/2001EP1153922A1 Heterodiazinone derivatives
1 ... 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 ... 647